We recently compiled a list of the 5 Stocks Jensen Huang’s Company is Betting On. In this article, we are going to take a ...

RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Background Cerebral arteriovenous malformations (AVMs) are complex lesions that can cause hemorrhagic stroke and significant neurological disability. Adenosine induces cardiac standstill and ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

a lead AI-derived candidate aimed at treating a fatal brain disease called cerebral cavernous malformation. CCM is characterized by an enlargement and irregularity in the shape of small blood vessels ...

Shares of 10 companies were hit hard on Thursday, bucking a mostly optimistic broader market, as investor sentiment was ...

Abstract: Familial cerebral cavernous malformation (FCCM) is a hereditary disorder characterized by abnormal vascular structures within the central nervous system. The FCCM lesions are often numerous ...

The following is a summary of “Risk factors for visual loss after excision of orbital cavernous venous malformations: a systematic review,” published in the January 2025 issue of Ophthalmology by ...